Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 2 clients • 6 examiners • 6 art units • 0 of 6 (0%) have an AI response strategy ready
Purdue - Flaster Greenberg P.C. operates in the Biotechnology & Pharmaceuticals sector, with 39 career applications. The firm has a resolved allowance rate of 50.0 percent. Prosecution typically requires an average of 4.0 office actions per allowance. There are 5 pending office actions currently under management.
The 50.0 percent allowance rate across 39 career applications suggests a challenging prosecution environment in the life sciences. The 4.0 office actions per allowance indicate that reaching an allowance often involves a significant number of interactions with the patent office. These figures highlight the complexity of securing patent rights in the biotechnology and pharmaceutical fields for this firm's clients.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 6 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 1 | 62.2% | +34.3% |
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| WORSHAM, JESSICA N | 1 | 56.3% | +56.3% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
| GURLEY, JAMI MICHELLE | 1 | 53.3% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794917 | LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THE USES THEREOF | GURLEY, JAMI MICHELLE | 53d overdue |
| 18034969 | NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT | WORSHAM, JESSICA N | 44d overdue |
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | COUGHLIN, MATTHEW P | 36d overdue |
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | OGUNBIYI, OLUWATOSIN A | 17d overdue |
| 18285439 | IMMUNOFUNCTIONAL CARRIER, METHODS OF USES, AND COMPOSITION MATTERS AS AN ANTITUMOR IMMUNOTHERAPY | DAVIS, BRIAN J | 3d overdue |
| 18702531 | NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING | FUBARA, BLESSING M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794917 | LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THE USES THEREOF | GURLEY, JAMI MICHELLE | 53d overdue |
| 18034969 | NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT | WORSHAM, JESSICA N | 44d overdue |
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | COUGHLIN, MATTHEW P | 36d overdue |
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | OGUNBIYI, OLUWATOSIN A | 17d overdue |
| 18702531 | NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING | FUBARA, BLESSING M | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Purdue University | 5 |
| Houston Methodist | 1 |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1614 | 1 |
| 1645 | 1 |
| 1615 | 1 |
| 1626 | 1 |
| 1647 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18702531 | NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING | Purdue Research Foundation | FUBARA, BLESSING M | 1613 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18285439 | IMMUNOFUNCTIONAL CARRIER, METHODS OF USES, AND COMPOSITION MATTERS AS AN ANTITUMOR IMMUNOTHERAPY | Purdue Research Foundation | DAVIS, BRIAN J | 1614 | §102§112 | Non-Final OA | 3d overdue | Pending | Oct 03, 2023 |
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | Houston Methodist Research Institute | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112 | Final Rejection | 17d overdue | Pending | Sep 11, 2023 |
| 18034969 | NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT | Purdue Research Foundation | WORSHAM, JESSICA N | 1615 | §102§103 | Final Rejection | 44d overdue | Pending | May 02, 2023 |
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | Purdue Research Foundation | COUGHLIN, MATTHEW P | 1626 | §102§112 | Non-Final OA | 36d overdue | Pending | Mar 17, 2023 |
| 17794917 | LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THE USES THEREOF | Purdue Research Foundation | GURLEY, JAMI MICHELLE | 1647 | §103§112 | Non-Final OA | 53d overdue | Pending | Jul 22, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial